TBA-7371

A DprE1 inhibitor being developed for tuberculosis. The patent is jointly held by TB Alliance and FNDR. Phase 2 Clinical trial was successfully carried out by Gates Medical Research Institute in South Africa (Trial No. NCT04176250)